Cure8 research brief
Patients with UC who appear healed on endoscopy can still relapse; a biopsy-based model could help separate lower- and higher-risk patients and guide monitoring or research enrollment.
Clinicians caring for UC patients in endoscopic remission, researchers studying biomarkers and relapse prediction, and adult UC patients interested in relapse risk stratification.
The authors ran a prospective multicenter cohort of 145 UC patients in endoscopic remission (Mayo 0–1), measured histology and immunohistochemical expression of Claudin‑2, VDR, and MUC‑2 on baseline biopsies, and developed a prespecified four-marker logistic model. In this cohort 24.8% relapsed within 12 months.
Higher Claudin‑2 and worse Nancy score were associated with higher relapse risk; higher VDR and MUC‑2 were associated with lower risk. The model showed very high discrimination in internal testing (apparent AUC 0.968; optimism-corrected AUC 0.957) but the study authors emphasize these are exploratory results.
Next steps and caution These findings are hypothesis-generating: the model was internally validated by bootstrap but lacks external validation, had a limited number of relapse events, and used site-specific immunohistochemistry methods that would need standardization before clinical use.
The work suggests tissue biomarkers warrant further study for risk stratification in UC with endoscopic healing.
This report is an abstract-based summary of a multicenter prospective cohort and includes internal (bootstrap) validation only. Results are exploratory and require external validation and standardized biomarker assays before clinical application.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
RDW is a cheap, routinely measured blood parameter; if it reliably reflects IBD presence or activity, it could be an easy additional tool to help detect flares or support assessment without extra testing.
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
A blood antibody (anti-integrin αvβ6) was associated with relapse risk in UC and may help predict who stays in long-term remission, which could affect monitoring and treatment planning.
